ADReCS

Pharmaceutical Information

Drug Name	Crizotinib
Drug ID	BADD_D00535
Description	Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status	approved
ATC Code	L01ED01
DrugBank ID	DB08865
KEGG ID	D09731
MeSH ID	D000077547
PubChem ID	11626560
TTD Drug ID	D03ZBT
NDC Product Code	68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII	53AH36668S
Synonyms	Crizotinib \| PF-02341066 \| PF-2341066 \| PF 2341066 \| PF2341066 \| PF 02341066 \| PF02341066 \| Xalkori

Chemical Information

Molecular Formula	C21H22Cl2FN5O
CAS Registry Number	877399-52-5
SMILES	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Dizziness postural	02.11.04.008; 17.02.05.004; 24.06.02.008	0.000470%		-
Dry throat	07.06.01.005; 22.12.03.005	0.000246%		-
Dysaesthesia	17.02.06.003; 23.03.03.077	-	-
Dysgeusia	07.14.03.001; 17.02.07.003	0.009089%
Dyspepsia	07.01.02.001	0.005865%
Dysphagia	07.01.06.003	0.012413%
Dyspnoea	02.11.05.003; 22.02.01.004	0.010633%
Dyspnoea exertional	02.11.05.005; 22.02.01.005	0.000694%		-
Ear haemorrhage	04.03.01.002; 12.01.14.004; 24.07.01.004	0.000112%		-
Ecchymosis	01.01.03.001; 23.06.01.001; 24.07.06.002	0.000112%		-
Electrocardiogram QT prolonged	13.14.05.004	-	-
Electrolyte imbalance	14.05.01.002	0.000526%		-
Embolism venous	24.01.01.003	0.000112%		-
Empyema	11.01.08.020	-	-	-
Enterocolitis	07.08.03.003	0.000168%
Eructation	07.01.02.003	0.000761%
Erythema multiforme	10.01.03.015; 23.03.01.003	0.000280%
Eye disorder	06.08.03.001	0.001097%		-
Eyelid ptosis	06.05.01.002; 17.17.02.004	0.000246%		-
Face oedema	08.01.07.003; 10.01.05.002; 23.04.01.004	-	-
Fatigue	08.01.01.002	0.022386%
Febrile neutropenia	01.02.03.002; 08.05.02.004	-	-
Fibrosis	08.03.01.001	0.000112%		-
Flank pain	08.01.08.007; 15.03.04.003; 20.02.03.006	0.000168%
Flatulence	07.01.04.002	0.002507%
Fluid retention	14.05.06.002; 20.01.02.003	0.002686%		-
Gait disturbance	08.01.02.002; 15.03.05.013; 17.02.05.016	-	-
Gamma-glutamyltransferase increased	13.03.04.024	-	-
Gastric perforation	07.04.03.001; 12.02.03.007	0.000168%
Gastritis	07.08.02.001	0.000604%

The 3th Page First Pre 3 4 5 6 7 Next Last Total 13 Pages